Comparing Metformin and Insulin for Gestational Diabetes Treatment
Official title: DECIDE: A Comparative Effectiveness Trial of Oral Metformin Versus Injectable Insulin for the Treatment of Gestational Diabetes
Run by Ohio State University · NCT06445946 · Data updated 2026-11-12
This study is testing whether metformin is as effective as insulin for treating gestational diabetes in pregnant people and looks at how safe both treatments are for mothers and their babies.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 1572 (estimated) |
| Sponsor | Ohio State University Academic / other |
| Locations | 26 sites (Tuscaloosa, Alabama and 25 other locations) |
| Status | Recruiting |
| Started | August 1, 2024 |
| Main results expected | December 2029 |
| Study ends | December 2030 |
| Registry record updated | October 7, 2026 |
| Trial ID | NCT06445946 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are pregnant individuals aged 18 and older diagnosed with gestational diabetes who require medication for glucose control.
✕Probably not a fit
Patients with renal disease, major fetal malformations, or contraindications to metformin or insulin will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This trial compares the effectiveness of metformin versus insulin in treating gestational diabetes mellitus (GDM) in pregnant individuals. It is a randomized controlled trial involving 1,572 participants across 20 U.S. sites, focusing on whether metformin is as effective as insulin in reducing adverse pregnancy outcomes. The study also aims to assess the safety of both treatments for mothers and their children, as well as to explore patient-reported experiences regarding the use of these medications. Participants will be followed from pregnancy through two years postpartum to gather comprehensive data.
Why it matters
Potential benefit: If successful, this study could provide evidence that metformin is a safe and effective alternative to insulin for managing gestational diabetes, potentially improving treatment options for patients.
How similar studies have gone: Previous studies have indicated that both metformin and insulin are effective for managing gestational diabetes, but this study aims to provide more definitive comparative effectiveness data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Singleton gestation. Twin reduction to singleton, either spontaneously or therapeutically, is eligible if it occurred before 14 weeks gestational age. * Age 18 years or older * Gestational age at randomization between 20 0/7 - 33 6/7 weeks based on project gestational age. * GDM diagnosis less than or equal to 33 6/7 weeks based on project gestational age. * Requires medication for glucose control defined as ≥ 30% elevated glucose values (either fasting or postprandial or both) prior to randomization per determination of the provider or documented in the medical record. * Patient willingness and ability to attend 2-year follow-up visit. Exclusion criteria: * Renal disease (serum creatinine \>1.3 mg/dL) due to the potential impact of metformin on renal function. * Major structural malformation of the fetus. * Known fetal aneuploidy based on invasive testing or positive for aneuploidy on cell-free fetal DNA screening. * Contraindication to metformin or insulin, including: history of lactic acidosis, intractable nausea and vomiting, prior documented allergy and/or anaphylaxis. * For individuals with GDM diagnosed \<20 0/7 weeks, documented A1c ≥\>6.5% within prior 6 months. * Pregestational diabetes documented in the medical record or prior A1c\>= 6.5% * Fasting hyperglycemia \>115 mg/dl for ≥ 50% of fasting glucose values in the past week (due to the high risk of metformin failure with fasting hyperglycemia). * Enrolled in a trial that influences primary study outcomes (composite neonatal outcome at delivery or childhood body mass index at 2 years). * Prenatal care or delivery planned at a location where access to the complete electronic medical record will not be available to research staff. * Language barrier (appropriate translation resources unavailable at the site) * Participation in this trial in a previous pregnancy. Patients who were screened in a previous pregnancy, but not randomized, may be included.
Where it's running
-
University of Alabama
Tuscaloosa, Alabama, United States Recruiting -
Cedars Sinai Medical Center
Los Angeles, California, United States Recruiting -
University of California San Francisco
San Francisco, California, United States Recruiting -
Yale School of Medicine
New Haven, Connecticut, United States Recruiting -
University of South Florida
Tampa, Florida, United States Recruiting -
Tufts University
Boston, Massachusetts, United States Recruiting
Show 20 more locations
-
Massachusetts General Hospital
Boston, Massachusetts, United States Recruiting -
Washington University in St. Louis
St Louis, Missouri, United States Recruiting -
University of New Mexico
Albuquerque, New Mexico, United States Recruiting -
Columbia University Irving Medical Center
New York, New York, United States Recruiting -
Wake Forest University
Winston-Salem, North Carolina, United States Recruiting -
The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine
Columbus, Ohio, United States Recruiting -
Premier Health - Miami Valley Hospital
Dayton, Ohio, United States Recruiting -
University of Pennsylvania
Philadelphia, Pennsylvania, United States Recruiting -
University of Pittsburgh
Pittsburgh, Pennsylvania, United States Recruiting -
Brown University
Providence, Rhode Island, United States Recruiting -
University of South Carolina Greenville
Greenville, South Carolina, United States Recruiting -
University of Texas Austin
Austin, Texas, United States Recruiting -
Austin Maternal Fetal Medicine
Austin, Texas, United States Recruiting -
University of Texas Health Science Center
Houston, Texas, United States Recruiting -
Eastern Virginia Medical School - Old Dominion University
Norfolk, Virginia, United States Recruiting -
Medical College of Wisconsin
Milwaukee, Wisconsin, United States Recruiting -
Christiana Care
Newark, Delaware, United States Withdrawn -
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States Terminated -
University of North Caroline
Chapel Hill, North Carolina, United States Withdrawn -
Kettering Health
Kettering, Ohio, United States Not yet recruiting
Study contacts
- Principal investigator: Kartik Venkatesh, MD, PhD — Ohio State University
- Study coordinator: Kartik Venkatesh, MD, PhD
- Email: kartik.venkatesh@osumc.edu
- Phone: 614-293-2222
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Islet function in gestational diabetes: see if pancreas changes during and after pregnancy
This study tests whether the human pancreas changes its function during and after pregnancy in people with gestational diabetes or not, using Exendin 9-39 in a small Phase 1 trial.
-
Prenatal Exercise to See How Cardio or Strength Training Affects Blood Sugar
This study tests whether different types and amounts of exercise during pregnancy can improve blood sugar control in women with gestational diabetes.
-
NOURISH: a community partnership to improve nutrition and glycemic control in pregnant women with pregestational diabetes
Aiming to test a healthcare-community program that delivers healthy food weekly and provides nutrition education to pregnant women with type 1 or type 2 diabetes who have food insecurity, to improve blood sugar and pregnancy outcomes.
-
MOCHA: Inpatient Mental Health Care for High-Risk Pregnancy
This study tests a collaborative mental health program for pregnant or recently postpartum patients hospitalized for medical problems to see if it can be delivered feasibly and acceptably.
-
Permissive versus strict blood sugar control during labor for pregnant people with type 1 diabetes
This trial will test whether allowing slightly higher blood sugars (70–140 mg/dL) during labor is as safe for newborns as keeping tighter control (70–110 mg/dL) for pregnant people with type 1 diabetes using hybrid closed‑loop insulin systems.
-
Home ultrasound in telemedicine care for gestational diabetes (GDM)
This study tests whether using a home ultrasound device at home, guided by a physician, improves satisfaction and outcomes for pregnant people with GDM compared to standard care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.